查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447038

到 2030 年α发射体市场预测 - 按类型（铅、砹、铋、镭、锕和其他类型）、来源、应用、最终用户和地理位置进行的全球分析

Alpha Emitter Market Forecasts to 2030 - Global Analysis By Type (Lead, Astatine, Bismuth, Radium, Actinium and Other Types), Source, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球α发射体市场规模为 6.784 亿美元，预计到 2030 年将达到 16.36 亿美元，预测期内复合CAGR为 13.4%。 α发射体是指经历α衰变并在此过程中发射α粒子的放射性物质或同位素。阿尔法粒子由两个质子和两个中子组成，本质上相当于氦 4 核。这种类型的放射性衰变的特征是从原子核中释放出α粒子，导致原始元素转变为原子序较低的新元素。 α发射体的使用在各个领域都有应用，包括医学、工业和研究。

根据国际癌症研究机构 (IARC) 的数据，到 2040 年，主要由于人口增长和老化，全球负担预计将增加到 2,750 万起活跃癌症事件和 1,630 万人癌症死亡。

市场动态：

司机：

对阿尔法粒子疗法的认识不断提高

市场意识正在不断提高，尤其是在阿尔法粒子疗法的认可度不断提高的推动下。随着医学科学的进步，人们对α发射体在标靶癌症治疗中的治疗潜力有了越来越多的了解。阿尔法粒子疗法提供高度局部和有效的辐射，增强其治疗某些类型癌症的功效，同时对周围健康组织的损害最小。不断提高的意识可能会推动对阿尔法发射体的需求，推动该领域的进一步创新和进步。

克制：

放射性药物的半衰期短

市面上放射性药物的半衰期短构成了挑战，限制了其在医疗和工业环境中的有效应用。快速腐烂减少了进行治疗或进行实验的机会之窗，需要高效的物流和快速部署。这项限制可能会影响阿尔法发射体的广泛采用，特别是在长时间的放射性对于预期结果至关重要的情况下，需要在规划和实施中仔细考虑衰减率。

机会：

核子医学的进展

核子医学市场的最新进展集中在创新的标靶α粒子疗法。阿尔法发射器透过向肿瘤细胞提供局部辐射，最大限度地减少对周围健康组织的损害，在癌症治疗中表现出高精度。这些进展提高了治疗介入措施的有效性和安全性，标誌着个人化医疗的重大进展，并改善了某些类型癌症患者的治疗结果。

威胁：

需要高额资金投入

由于阿尔法发射技术的复杂性和专业性，市场需要大量的资本投资。建立安全的生产设施、确保遵守严格的监管标准以及投资安全应用的先进研发需要大量的财政资源。此外，对广泛的安全措施和受控环境的需求增加了总体的高资本要求，为潜在的市场参与者设置了进入障碍。

Covid-19 影响：

COVID-19 大流行扰乱了供应链、推迟了研发项目并影响了监管流程，从而影响了市场。大流行期间对医疗保健的日益关注对医疗应用中使用的阿尔法发射体的需求产生了积极和消极的影响。虽然癌症治疗的需求不断增长，但后勤挑战和资源优先顺序带来了障碍。由于全球健康危机造成的动态环境，整个市场经历了波动。

预计铋业务在预测期内将是最大的业务

预计铋业务在预测期内将是最大的业务。它用于靶向α粒子放射治疗，以治疗某些类型的癌症。其半衰期短且能够输送高能量阿尔法粒子，这使其对于精确有效的癌症治疗具有重要价值。对创新医疗疗法的日益关注导致对 bismuth-213 的需求不断增长，并强调了其在推进 α 发射体在医疗领域应用的重要性。

预计卵巢癌领域在预测期内的CAGR最高

预计卵巢癌领域在预测期内的CAGR最高。这种有针对性的方法可以最大限度地减少对周围健康组织的损害。然而，监管批准、安全考虑以及进一步临床证据的需要可能会影响其广泛采用。卵巢癌治疗和研究不断发展的前景将影响α发射体在解决这一具有挑战性的疾病中的作用。

占比最大的地区：

由于医疗应用（特别是癌症治疗）的增加，预计北美在预测期内将占据最大的市场份额。对核电和研发活动的投资不断增加有助于市场扩张。公众认知和监管合规仍然是影响该地区阿尔法排放者成长的关键因素。

复合CAGR最高的地区：

由于医疗、研究和核能发电方面的应用不断增加，预计亚太地区在预测期内的CAGR最高。癌症盛行率的上升推动了对标靶α粒子放射治疗的需求。该地区不断扩大的医疗保健产业和研究活动有助于发挥该地区的潜力，但持续的发展和对安全协议的遵守将在塑造该地区市场轨迹方面发挥关键作用。

主要进展：

2022年11月，分子影像诊断和治疗公司IONETIX公司宣布，美国核能管理委员会（NRC）为其位于美国密西根州的新生产设施颁发了材料许可证

2022年6月，医疗科技公司Alpha Tau Medical Ltd.宣布美国食品药物管理局（FDA）已批准其研究器械豁免（IDE）申请，启动其治疗復发性皮肤鳞状细胞癌的多中心关键研究使用Alpha DaRT 进行细胞癌(SCC)。

我们的报告提供了什么：

  • 区域和国家层面的市场份额评估
  • 对新进入者的策略建议
  • 涵盖2021年、2022年、2023年、2026年及2030年的市场资料
  • 市场趋势（驱动因素、限制因素、机会、威胁、挑战、投资机会和建议）
  • 根据市场预测提出关键业务部门的策略建议
  • 竞争性景观美化绘製主要共同趋势
  • 公司概况，包括详细的策略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费客製化产品：

本报告的所有客户都将有权获得以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 个）
    • 关键参与者的 SWOT 分析（最多 3 个）
  • 区域细分
    • 根据客户的兴趣对任何主要国家的市场估计、预测和CAGR（註：取决于可行性检查）
  • 竞争基准化分析
    • 根据产品组合、地理分布和策略联盟对主要参与者基准化分析

目录

第 1 章：执行摘要

第 2 章：前言

  • 抽象的
  • 股东
  • 研究范围
  • 研究方法论
    • 资料探勘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第 3 章：市场趋势分析

  • 介绍
  • 司机
  • 限制
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • Covid-19 的影响

第 4 章：波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争竞争

第 5 章：全球α发射体市场：按类型

  • 介绍
  • 带领
  • 砈
  • 铋
  • 镭
  • 锟
  • 其他类型

第 6 章：全球α发射体市场：依来源分类

  • 介绍
  • 人工产生的来源
  • 天然来源

第 7 章：全球α发射体市场：按应用分类

  • 介绍
  • 摄护腺癌
  • 神经内分泌肿瘤
  • 骨转移
  • 卵巢癌
  • 其他应用

第 8 章：全球α发射体市场：按最终用户划分

  • 介绍
  • 专科诊所
  • 诊断中心
  • 医院
  • 其他最终用户

第 9 章：全球α发射体市场：依地理位置

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 南非
    • 中东和非洲其他地区

第 10 章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 扩充
  • 其他关键策略

第 11 章：公司概况

  • Orano Group
  • Alpha Tau Medical Ltd
  • Actinium Pharmaceutical Inc.
  • Novartis International AG
  • Bayer AG
  • NorthStar Medical Radioisotopes
  • Fusion Pharmaceuticals Inc.
  • Telix Pharmaceuticals Ltd
  • Eckert & Ziegler
  • RadioMedix
  • Curium Pharma
  • Isotopen Technologien Munchen AG (ITM)
  • Nordion Inc.
Product Code: SMRC25299

According to Stratistics MRC, the Global Alpha Emitter Market is accounted for $678.4 million in 2023 and is expected to reach $1636.0 million by 2030 growing at a CAGR of 13.4% during the forecast period. An alpha emitter refers to a radioactive substance or isotope that undergoes alpha decay, emitting alpha particles during the process. Alpha particles consist of two protons and two neutrons, essentially equivalent to a helium-4 nucleus. This type of radioactive decay is characterized by the release of alpha particles from the atomic nucleus, resulting in the transformation of the original element into a new element with a lower atomic number. The use of alpha emitters has applications in various fields, including medicine, industry, and research.

According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging.

Market Dynamics:

Driver:

Rising awareness of alpha particle therapy

The market is experiencing a surge in awareness, particularly driven by the growing recognition of alpha particle therapy. As medical science advances, there is an increasing understanding of the therapeutic potential of alpha emitters in targeted cancer treatments. Alpha particle therapy delivers highly localized and potent radiation, enhancing its efficacy in treating certain types of cancers with minimal damage to surrounding healthy tissues. The rising awareness is likely to propel the demand for alpha emitters, driving further innovations and advancements in this field.

Restraint:

Short half-life of radiopharmaceuticals

The short half-life of radiopharmaceuticals in the market poses a challenge, limiting their effective application in medical and industrial settings. Rapid decay reduces the window of opportunity for administering treatments or conducting experiments, requiring efficient logistics and quick deployment. This constraint may impact the widespread adoption of alpha emitters, especially in scenarios where extended periods of radioactivity are crucial for desired outcomes, necessitating careful consideration of decay rates in planning and implementation.

Opportunity:

Advancements in nuclear medicine

Recent advancements in the market for nuclear medicine have focused on innovative targeted alpha-particle therapies. Alpha emitters exhibit high precision in cancer treatment by delivering localized radiation to tumour cells, minimizing damage to surrounding healthy tissues. These developments enhance the efficacy and safety of therapeutic interventions, marking significant progress in personalized medicine and improving outcomes for patients with certain types of cancer.

Threat:

Need for high capital investment

The market demands substantial capital investment due to the complex and specialized nature of alpha-emitting technologies. Establishing secure production facilities, ensuring compliance with stringent regulatory standards, and investing in advanced research and development for safe applications require significant financial resources. Additionally, the need for extensive safety measures and controlled environments adds to the overall high capital requirements, creating a barrier to entry for potential market participants.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by disrupting supply chains, delaying research and development projects, and impacting regulatory processes. The increased focus on healthcare during the pandemic has both positively and negatively affected the demand for alpha emitters used in medical applications. While the need for cancer treatments has grown, logistical challenges and prioritization of resources have presented obstacles. The overall market has experienced fluctuations due to the dynamic circumstances created by the global health crisis.

The bismuth segment is expected to be the largest during the forecast period

The bismuth segment is expected to be the largest during the forecast period. It is utilized in targeted alpha-particle radiotherapy for treating certain types of cancer. Its short half-life and ability to deliver high-energy alpha particles make it valuable for precise and effective cancer treatment. The increasing focus on innovative medical therapies has contributed to the growing demand for bismuth-213 and underscores its importance in advancing alpha emitter applications in the medical field.

The ovarian cancer segment is expected to have the highest CAGR during the forecast period

The ovarian cancer segment is expected to have the highest CAGR during the forecast period. This targeted approach minimizes damage to surrounding healthy tissue. However, regulatory approvals, safety considerations, and the need for further clinical evidence may impact their widespread adoption. The evolving landscape of ovarian cancer treatments and research will influence the role of alpha emitters in addressing this challenging disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to increasing applications in medical treatments, particularly in cancer therapy. Growing investments in nuclear power and research and development activities contribute to market expansion. Public perception and regulatory compliance remain pivotal factors influencing the growth of alpha emitters in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to increasing applications in medical treatments, research, and nuclear power generation. Rising prevalence of cancer fuels demand for targeted alpha-particle radiotherapy. The region's expanding healthcare sector and research activities contribute to the region's potential, but ongoing developments and adherence to safety protocols will play pivotal roles in shaping the trajectory of the market in this region.

Key players in the market

Some of the key players in Alpha Emitter market include Orano Group, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Novartis International AG, Bayer AG, NorthStar Medical Radioisotopes, Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd, Eckert & Ziegler, RadioMedix, Curium Pharma, Isotopen Technologien Munchen AG (ITM), Nordion Inc..

Key Developments:

In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S.

In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.

Types Covered:

  • Lead
  • Astatine
  • Bismuth
  • Radium
  • Actinium
  • Other Types

Sources Covered:

  • Artificially Produced Sources
  • Natural Sources

Applications Covered:

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Bone Metastases
  • Ovarian Cancer
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Diagnostic Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Researh Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Alpha Emitter Market, By Type

  • 5.1 Introduction
  • 5.2 Lead
  • 5.3 Astatine
  • 5.4 Bismuth
  • 5.5 Radium
  • 5.6 Actinium
  • 5.7 Other Types

6 Global Alpha Emitter Market, By Source

  • 6.1 Introduction
  • 6.2 Artificially Produced Sources
  • 6.3 Natural Sources

7 Global Alpha Emitter Market, By Application

  • 7.1 Introduction
  • 7.2 Prostate Cancer
  • 7.3 Neuroendocrine Tumors
  • 7.4 Bone Metastases
  • 7.5 Ovarian Cancer
  • 7.6 Other Applications

8 Global Alpha Emitter Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Diagnostic Centers
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Alpha Emitter Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Orano Group
  • 11.2 Alpha Tau Medical Ltd
  • 11.3 Actinium Pharmaceutical Inc.
  • 11.4 Novartis International AG
  • 11.5 Bayer AG
  • 11.6 NorthStar Medical Radioisotopes
  • 11.7 Fusion Pharmaceuticals Inc.
  • 11.8 Telix Pharmaceuticals Ltd
  • 11.9 Eckert & Ziegler
  • 11.10 RadioMedix
  • 11.11 Curium Pharma
  • 11.12 Isotopen Technologien Munchen AG (ITM)
  • 11.13 Nordion Inc.

List of Tables

  • Table 1 Global Alpha Emitter Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 4 Global Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 5 Global Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 6 Global Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 7 Global Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 8 Global Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 10 Global Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 11 Global Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 12 Global Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 13 Global Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 14 Global Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 15 Global Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 16 Global Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 17 Global Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 18 Global Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 19 Global Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 20 Global Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 21 Global Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 23 North America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 24 North America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 25 North America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 26 North America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 27 North America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 28 North America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 29 North America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 30 North America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 32 North America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 33 North America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 34 North America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 North America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 36 North America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 37 North America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 38 North America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 39 North America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 40 North America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 41 North America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 42 North America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 43 North America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 44 North America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 45 Europe Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 46 Europe Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 48 Europe Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 49 Europe Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 50 Europe Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 51 Europe Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 52 Europe Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 53 Europe Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 54 Europe Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 55 Europe Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 56 Europe Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 57 Europe Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 58 Europe Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 59 Europe Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 60 Europe Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 61 Europe Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 62 Europe Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 63 Europe Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 64 Europe Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 65 Europe Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 66 Europe Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 67 Asia Pacific Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 68 Asia Pacific Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 69 Asia Pacific Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 70 Asia Pacific Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 71 Asia Pacific Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 72 Asia Pacific Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 73 Asia Pacific Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 74 Asia Pacific Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 76 Asia Pacific Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 77 Asia Pacific Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 78 Asia Pacific Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 79 Asia Pacific Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 80 Asia Pacific Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 81 Asia Pacific Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 82 Asia Pacific Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 83 Asia Pacific Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 84 Asia Pacific Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 85 Asia Pacific Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 86 Asia Pacific Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 87 Asia Pacific Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 88 Asia Pacific Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 89 South America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 90 South America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 91 South America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 92 South America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 93 South America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 94 South America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 95 South America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 96 South America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 97 South America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 98 South America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 99 South America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 100 South America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 101 South America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 102 South America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 103 South America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 104 South America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 105 South America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 106 South America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 107 South America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 108 South America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 109 South America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 110 South America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 111 Middle East & Africa Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
  • Table 112 Middle East & Africa Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
  • Table 113 Middle East & Africa Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
  • Table 114 Middle East & Africa Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
  • Table 115 Middle East & Africa Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
  • Table 116 Middle East & Africa Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
  • Table 117 Middle East & Africa Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
  • Table 118 Middle East & Africa Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 119 Middle East & Africa Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
  • Table 120 Middle East & Africa Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
  • Table 121 Middle East & Africa Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
  • Table 122 Middle East & Africa Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
  • Table 123 Middle East & Africa Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 124 Middle East & Africa Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 125 Middle East & Africa Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
  • Table 126 Middle East & Africa Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 127 Middle East & Africa Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 128 Middle East & Africa Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
  • Table 129 Middle East & Africa Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 130 Middle East & Africa Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 131 Middle East & Africa Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 132 Middle East & Africa Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)